Sex hormones (9)
Hormonal agents (7)
Androgen esters (2)
Blister agents (2)
Sigma Aldrich (2)
AK Scientific (1)
Oakwood Chemical (1)
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow.
Teslac · delta(1)-Testolactone · Bristol-Myers Squibb Brand of Testolactone
Testolactone (INN, USAN) (brand name Teslac) is a non-selective, irreversible, steroidal aromatase inhibitor which is used as an antineoplastic drug to treat advanced-stage breast cancer. The drug was discontinued in 2008 and is no longer available for medical use.
Medroxyprogesterone acetate (71-58-9)
Provera · DepoProvera · Depo Provera
Medroxyprogesterone acetate (MPA), sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. It is used as birth control and as part of menopausal hormone therapy. It is also used to treat endometriosis, abnormal uterine bleeding, abnormal sexuality in males, and certain types of cancer.
Formestane, sold under the brand name Lentaron among others, is a steroidal, selective aromatase inhibitor which is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and is instead available only as an intramuscular depot injection. Because of this, it is no longer popular as many orally active aromatase inhibitors have been identified and introduced.
Atamestane (developmental code name SH-489), also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer. It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase.
LS-1727, also known as nandrolone 17β-N-(2-chloroethyl)-N-nitrosocarbamate, is a synthetic, injected anabolic–androgenic steroid (AAS) and a nitrosocarbamate ester of nandrolone (19-nortestosterone) that was developed as an alkylating antineoplastic agent but was never marketed.